Best peptides for muscle and recovery

Why muscle mass matters more than you think

Bodybuilding has an image problem. People assume it's purely about aesthetics, but the science says otherwise. Dr. Peter Attia, in Outlive and on his podcast, argues that muscle is the "organ of longevity." Sarcopenia, the age-related loss of muscle mass and strength, is one of the strongest predictors of all-cause mortality in older adults. Low muscle mass correlates with higher rates of falls, fractures, metabolic disease, and loss of independence.

So building and maintaining muscle isn't vanity. It's arguably the highest-leverage health intervention available to most people. Resistance training does the heavy lifting (literally), but a growing number of people are adding peptides to support muscle growth, recovery, and body composition.

Here's what the evidence actually says about the peptides bodybuilders talk about most.

Growth hormone secretagogues: the core category

Growth hormone (GH) drives muscle protein synthesis, fat metabolism, and tissue repair. GH output drops roughly 14% per decade after age 30. Growth hormone secretagogues (GHSs) stimulate your pituitary gland to produce more of its own GH rather than replacing it with exogenous injections.

The GHSs that come up most in bodybuilding circles:

• CJC-1295 (Modified GRF 1-29) is a synthetic GHRH analog that stimulates GH release through the GHRH receptor. Usually refers to the version without DAC, which produces acute GH pulses with a half-life of about 30 minutes.
• Ipamorelin is a selective ghrelin-receptor agonist that triggers GH release without significantly raising cortisol, prolactin, or appetite. Raun et al. (1998) showed dose-dependent GH release with a clean side-effect profile.
• MK-677 (ibutamoren) isn't technically a peptide. It's an oral ghrelin mimetic that raises GH and IGF-1 levels over 24 hours. Murphy et al. (1998) showed sustained IGF-1 elevation over 12 months.
• Sermorelin is a truncated version of natural GHRH (the first 29 amino acids). It was FDA-approved for pediatric GH deficiency before being discontinued for commercial reasons, which gives it more clinical data than most peptides in this category.

How GH peptides differ from exogenous HGH

This distinction gets glossed over too often. Injecting recombinant human growth hormone (rhGH) delivers a flat, supraphysiological dose that suppresses your pituitary's own production through negative feedback. Over time, your body makes less GH on its own.

GH secretagogues work differently. They push the pituitary to release GH in pulses, preserving the natural pulsatile pattern the body uses to regulate growth, repair, and metabolism. Your hypothalamic feedback loops stay intact. You get a GH elevation that looks more like what a younger version of you would produce naturally.

The trade-off is magnitude. Exogenous HGH can push GH and IGF-1 far beyond physiological ranges, which is why competitive bodybuilders chasing extreme mass still use it. Secretagogues produce more modest elevations, typically raising IGF-1 by 1.5- to 3-fold. That's more appropriate for people who want better recovery and body composition without the risks of supraphysiological dosing: joint pain, insulin resistance, organ growth.

The synergistic stack: CJC-1295 + ipamorelin

The most popular GH peptide combination pairs CJC-1295 with Ipamorelin. They act on different receptors (GHRH and ghrelin, respectively) on the same pituitary somatotroph cells. Arvat et al. (2001) showed that co-administering GHRH and ghrelin-pathway agonists produces GH responses substantially greater than the sum of either compound alone.

Neither compound raises cortisol or prolactin much, and neither drives the appetite stimulation you get with MK-677. If you want GH support without battling constant hunger or metabolic side effects, this combo has the best profile of the available options.

Recovery peptides: BPC-157 and TB-500

Training hard enough to grow means training hard enough to get hurt. Two peptides come up constantly in recovery discussions:

BPC-157 (Body Protection Compound-157) is a 15-amino-acid peptide derived from a protein in human gastric juice. Animal studies show it promotes angiogenesis, modulates the nitric oxide system, and reduces inflammation. It has been studied in rodent models of tendon, ligament, muscle, and nerve injuries with consistently positive results.

TB-500 (a synthetic fragment of Thymosin Beta-4) works through a different mechanism. It regulates actin dynamics to promote cell migration to injury sites and reduces fibrosis (scar tissue formation). Unlike BPC-157, Thymosin Beta-4 has some human clinical trial data from ophthalmic studies.

People often stack these two together. The reasoning: BPC-157 creates conditions for healing (blood supply, reduced inflammation) while TB-500 handles the cellular mechanics of repair (cell migration, tissue remodeling). No published studies have examined this combination directly, though.

Note: BPC-157 has no completed human clinical trials as of early 2026. Both BPC-157 and TB-500 are prohibited by WADA under category S0. Most research is preclinical.

The GLP-1 problem for bodybuilders

Semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) have transformed weight loss. But bodybuilders face a specific problem with these compounds: muscle loss.

In the STEP 1 trial, roughly 40% of the weight lost on semaglutide was lean mass, not fat. If your primary goal is building or preserving muscle, losing nearly half a pound of muscle for every pound of fat is a terrible trade. Tirzepatide showed similar lean mass losses in the SURMOUNT trials.

This isn't unique to GLP-1 drugs. Any big caloric deficit causes lean mass loss. But the appetite suppression from GLP-1 agonists can be so extreme that users drastically undereat protein without realizing it, which accelerates muscle wasting.

Ways bodybuilders try to offset this:

• High protein intake at 1 g+ per pound of body weight daily, even when appetite is gone
• Resistance training, which is the single most protective factor against lean mass loss during a deficit
• GH secretagogue stacking by combining GLP-1 agonists with CJC-1295 + Ipamorelin or MK-677 to support lean mass retention (clinical evidence for this specific combination is limited)
• Slower dose titration to reduce the severity of appetite suppression

Practical stacking considerations

Peptide stacking is common in practice but rarely studied in clinical settings. Here are the combinations that come up most:

Timing matters. GH secretagogues should be taken on an empty stomach (fasting 2-3 hours) because insulin and free fatty acids blunt the GH response. Most people dose before bed, when the largest natural GH pulse occurs during deep sleep.

Why the evidence varies so widely

If you research these peptides, you'll find everything from peer-reviewed clinical trials to anecdotes on Reddit. The reason for this spread:

• Sermorelin and MK-677 have the most clinical data because pharmaceutical companies developed them and put them through formal trials.
• CJC-1295 reached Phase I/II trials before development stalled.
• Ipamorelin was studied in a Phase II trial for post-operative ileus, not bodybuilding.
• BPC-157 has extensive animal data but zero completed human trials.
• TB-500 benefits from human trial data on its parent compound (Thymosin Beta-4), but those trials studied eye conditions, not musculoskeletal repair.

None of these peptides are FDA-approved for muscle growth or bodybuilding. For most of them, there's a wide gap between what animal studies suggest and what's been proven in humans. That doesn't mean they don't work, but you're making decisions with incomplete information, and you should know that going in.

Sources

1. Attia P. Outlive: The Science and Art of Longevity. Harmony Books. 2023.
2. Teichman SL, et al. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295 in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805.
3. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561.
4. Nass R, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Ann Intern Med. 2008;149(9):601-611.
5. Arvat E, et al. Endocrine activities of ghrelin: comparison and interactions with hexarelin and GH-releasing hormone. J Clin Endocrinol Metab. 2001;86(3):1169-1174.
6. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002.
7. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216.
8. Sikiric P, et al. Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications. Current Neuropharmacology. 2016;14(8):857-865.
9. Goldstein AL, et al. Thymosin beta-4: actin-sequestering protein moonlights to repair injured tissues. Trends in Molecular Medicine. 2005;11(9):421-429.
10. Veldhuis JD, et al. Somatotropic and gonadotropic axes linkages in infancy, childhood, and the puberty-adult transition. Endocrine Reviews. 2006;27(2):101-140.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. None of the peptides discussed here are FDA-approved for bodybuilding or muscle growth. Peptide use carries risks including unknown long-term side effects, contamination from unregulated sources, and drug interactions. Always consult a qualified healthcare provider before using any peptide or research compound.